Heron Therapeutics, Inc. (HRTX) has a negative trailing P/E of -6.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 7.4 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -15.08%, forward earnings yield 13.59%. PEG 0.15 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 58/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -2.9 | -0.05 | -23.38 | 388.44 | - |
| 2017 | -5.0 | 0.25 | 7.46 | 31.79 | - |
| 2018 | -10.6 | 0.32 | 5.13 | 24.51 | - |
| 2019 | -9.4 | -3.82 | 4.76 | 13.17 | - |
| 2020 | -8.5 | 0.00 | 8.12 | 21.68 | - |
| 2021 | -4.1 | 0.39 | 11.59 | 10.41 | - |
| 2022 | -1.5 | 0.06 | 20.08 | 2.53 | - |
| 2023 | -2.1 | 0.04 | -6.91 | 1.85 | - |
| 2024 | -17.2 | 0.19 | -6.93 | 1.62 | - |
| 2025 | -10.7 | -0.31 | 15.12 | 1.40 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-4.57 | $1.28M | $-173.14M | -13537.4% |
| 2017 | $-3.65 | $30.77M | $-197.48M | -641.9% |
| 2018 | $-2.44 | $77.47M | $-178.84M | -230.8% |
| 2019 | $-2.50 | $145.97M | $-204.75M | -140.3% |
| 2020 | $-2.47 | $88.64M | $-224.43M | -253.2% |
| 2021 | $-2.21 | $86.35M | $-217.66M | -252.1% |
| 2022 | $-1.24 | $107.67M | $-134.52M | -124.9% |
| 2023 | $-0.80 | $192.15M | $-110.56M | -57.5% |
| 2024 | $-0.09 | $144.29M | $-13.58M | -9.4% |
| 2025 | $-0.12 | $154.9M | $-20.2M | -13% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.02 | $-0.02 – $-0.01 | $175.07M | $172.77M – $177.36M | 1 |
| 2027 | $0.13 | $0.13 – $0.13 | $210.6M | $204.63M – $216.69M | 1 |
| 2028 | $0.30 | $0.21 – $0.39 | $254.35M | $247.14M – $261.71M | 2 |
| 2029 | $0.37 | $0.35 – $0.38 | $295.85M | $287.47M – $304.41M | 1 |
| 2030 | $0.44 | $0.42 – $0.46 | $329M | $319.68M – $338.51M | 1 |
